OBJECTIVES: Since insulin resistance can promote endothelial dysfunction, and anti-TNF-α treatment improves endothelial function in ankylosing spondylitis (AS) patients, in the present study we sought to assess whether an infusion of the anti-TNF-α monoclonal antibody-infliximab may improve insulin sensitivity in non-diabetic AS patients. METHODS: We assessed a series of 30 non-diabetic patients with AS attending hospital outpatient clinics who fulfilled the modified New York diagnostic criteria for AS. In all cases, the drug was given as an intravenous infusion in a saline solution over 120 minutes. Fasting blood samples were taken for determination of plasma glucose and serum insulin levels immediately before (time 0) and after infliximab infusion (time 120). RESULTS: At the time of the study only 8 (26.7%) of the 30 patients fulfilled definitions for insulin resistance as HOMA index was in most cases less than 2.29. Nevertheless, a statistically significant reduction in the HOMA values was observed when results found at time 0 (mean±SD: 1.72±1.22) were compared with those observed immediately after infliximab infusion (1.18±0.94) (p<0.001). The reduction in HOMA values was more important in those patients with the higher values of HOMA before infliximab infusion. Also, a significant improvement of insulin sensitivity was observed in most patients when QUICKI values before (0.37±0.04) and after infusion (0.39±0.04) were compared (p=0.004). CONCLUSIONS: The present study shows that non-diabetic patients with AS on treatment with infliximab experience a rapid improvement of insulin sensitivity following administration of this drug.
OBJECTIVES: Since insulin resistance can promote endothelial dysfunction, and anti-TNF-α treatment improves endothelial function in ankylosing spondylitis (AS) patients, in the present study we sought to assess whether an infusion of the anti-TNF-α monoclonal antibody-infliximab may improve insulin sensitivity in non-diabetic AS patients. METHODS: We assessed a series of 30 non-diabeticpatients with AS attending hospital outpatient clinics who fulfilled the modified New York diagnostic criteria for AS. In all cases, the drug was given as an intravenous infusion in a saline solution over 120 minutes. Fasting blood samples were taken for determination of plasma glucose and serum insulin levels immediately before (time 0) and after infliximab infusion (time 120). RESULTS: At the time of the study only 8 (26.7%) of the 30 patients fulfilled definitions for insulin resistance as HOMA index was in most cases less than 2.29. Nevertheless, a statistically significant reduction in the HOMA values was observed when results found at time 0 (mean±SD: 1.72±1.22) were compared with those observed immediately after infliximab infusion (1.18±0.94) (p<0.001). The reduction in HOMA values was more important in those patients with the higher values of HOMA before infliximab infusion. Also, a significant improvement of insulin sensitivity was observed in most patients when QUICKI values before (0.37±0.04) and after infusion (0.39±0.04) were compared (p=0.004). CONCLUSIONS: The present study shows that non-diabeticpatients with AS on treatment with infliximab experience a rapid improvement of insulin sensitivity following administration of this drug.
Authors: Fernanda Genre; Raquel López-Mejías; José A Miranda-Filloy; Begoña Ubilla; Verónica Mijares; Beatriz Carnero-López; Inés Gómez-Acebo; Trinidad Dierssen-Sotos; Sara Remuzgo-Martínez; Ricardo Blanco; Trinitario Pina; Carlos González-Juanatey; Javier Llorca; Miguel A González-Gay Journal: Rheumatol Int Date: 2015-07-05 Impact factor: 2.631
Authors: Thiago Gagliano-Jucá; M Furkan Burak; Karol M Pencina; Zhuoying Li; Robert R Edwards; Thomas G Travison; Shehzad Basaria Journal: J Clin Endocrinol Metab Date: 2018-10-01 Impact factor: 5.958
Authors: Hoda E Mohamed; Mervat E Asker; Mohammed M Keshawy; Rehab A Hasan; Yasmin K Mahmoud Journal: Mol Cell Biochem Date: 2020-01-13 Impact factor: 3.842
Authors: Fernanda Genre; Raquel López-Mejías; José A Miranda-Filloy; Begoña Ubilla; Beatriz Carnero-López; Ricardo Blanco; Trinitario Pina; Carlos González-Juanatey; Javier Llorca; Miguel A González-Gay Journal: Biomed Res Int Date: 2014-03-18 Impact factor: 3.411